Navigation Links
Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress
Date:10/18/2011

tar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact: Emily Forest, Marketing Manager, at 339-298-2156.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE CBI
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
2. TechConnect World Publishes Conference Agenda Featuring More than 2,700 Presentations Addressing Nano, Bio and Clean Technologies
3. American Society of Anesthesiologists Primary Agenda Displayed Says Dr. Barry Friedberg of Cosmetic Surgery Anesthesia
4. CBI Announces the Agenda for Their West Coast Forum on Clinical Supply Chain Management
5. CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress
6. 'Biopolymers Symposium 2010' Agenda Announced
7. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
8. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
9. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
10. First Annual Arizona Biotech Day Announced for October 23rd 2008
11. Presenters Announced For MichBio Expos Emerging Business Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  US-Australian drug discovery company, Novogen Limited ... its comprehensive scientific review has identified high value ... of unmet patient need. Novogen is moving as ... prior to entering into Phase 1 clinical trials ... Chief Executive Officer, Iain Ross , said ...
(Date:8/31/2015)... , Aug. 31, 2015 LabStyle Innovations ... Management Solution, today announced it recently closed a ... will be used to support the global rollout ... a mobile, cloud-based, diabetes management solution that includes ... pocket-sized, blood glucose monitoring device, and for working ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food Processing ... and beverage processors, equipment manufacturers and leaders in the field of academia. ... and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, poultry and ...
(Date:8/30/2015)... , England , August 31, ... beendet die 51-jährige Wartezeit   einer Frau   für ... Frauen im Alter von 7-90   werden ... Programm soll 1200 Frauen behandeln und die ... , Astellas gab heute bekannt, ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... for Ipilimumab to be Presented -PRINCETON, N.J., April 29 ... today that the following clinical abstracts for ipilimumab in ... anti-PD-1 antibody for cancer treatment, have been selected to ... of the American Society of Clinical Oncology, being held ...
... In an effort to provide technology to reduce ... early-phase medical device company, has demonstrated its patented ... is designed to protect hospital patients and medical ... healthcare facilities. It enables effective, frequent and instantaneous ...
... EPS increased 16.0 percent to $0.58 from $0.50 ... amortization of intangible assets from the 2003 spin-off, ... first-quarter 2008- Total net revenues increased 14.4 percent ... increased 21.0 percent to a record $2.3 billion- ...
Cached Biology Technology:Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 4Germgard's Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus 2Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 2Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 3Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 4Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 5Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 6Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 7Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 8Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 9Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 10Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 11Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 12Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 13Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 14Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 15Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 16Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 17Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 18Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 19Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 20Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 21Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 22Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 23
(Date:9/1/2015)... Sept. 1, 2015  Automation and pre-processing are ... passenger screening. This is the first step toward ... will become unintrusive. An assortment of portal scanners, ... background investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( ...
(Date:8/31/2015)... , August 31, 2015 Growing ... technology in government digitization projects to drive India ... recently published TechSci Research report, " India Biometrics Market Forecast ... is projected to grow at a CAGR of ... is anticipated on account of extensive use of biometric technology ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Saudi Arabia Biomedical Sensors market is estimated at $0.23 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2
... rate of chemical processes in cells is dictated by the ... reaction. Using a versatile method developed at the Institute of ... researchers were able to predict for the first time the ... The achievement is important not only for biologists and chemists, ...
... of the range and habits of white-backed vultures across ... preferring to forage further afield on private farmland. ... means that vultures risk encountering dead cattle that have ... or even poisoned carcasses intended to control other carnivores ...
... damage is closer following research by scientists at Monash University. ... the Australian Regenerative Medicine Institute at Monash University are closer ... They have, for the first time, derived and purified lens ... the eye develops. The purity of the cells paves the ...
Cached Biology News:Biologistics: How fast do chemical trains move in living cells? 2Biologistics: How fast do chemical trains move in living cells? 3Vultures foraging far and wide face a poisonous future 2Vultures foraging far and wide face a poisonous future 3'Petri dish lens' gives hope for new eye treatments 2
...
BD IMagnet 1 each...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Biology Products: